Novo Nordisk's Subscription Gambit to Defend a Shrinking Top Line

Novo Nordisk offers Wegovy subscription savings as competition heats up. The firm also gains a key EU storage win for its weight-loss drug ahead of crucial Q1 results.

Novo Nordisk is pulling a new lever in the escalating battle for weight-loss drug patients. To counter the competitive threat from Eli Lilly's daily pill Foundayo, the Danish pharmaceutical giant has launched a subscription model for its blockbuster Wegovy, offering annual savings of up to $1,200 for U.S. patients. This aggressive pricing move comes as the company braces for a year of declining sales, with management forecasting a currency-adjusted revenue drop of 5% to 13% for 2026.

The strategic pivot underscores the pressure on Novo Nordisk's pricing power. The broad availability of Eli Lilly's oral GLP-1 alternative has intensified market competition, forcing the Wegovy maker to focus on patient retention. The subscription program is designed to bolster long-term therapy adherence and prevent switches to cheaper alternatives or compounded versions of the drug.

Amid this commercial pressure, the company secured a quiet but significant regulatory win in Europe. The European Medicines Agency (EMA) has updated Wegovy's product information to allow storage at temperatures up to 30 degrees Celsius for 48 hours, eliminating the previous requirement for an unbroken cold chain. This logistical flexibility, unique among GLP-1 weight-loss drugs in Europe, significantly reduces distribution costs and makes home delivery services via eHealth channels more feasible.

Investor sentiment remains cautious, reflected in a share price that has fallen roughly 28% since the start of the year. The stock closed at €32.08 on Friday, hovering just above its 52-week low. A nearly 19% decline in short positions during March provided some minor technical support, but the overarching narrative is one of transition.

All eyes are now on May 6, when Novo Nordisk reports its first-quarter results. The figures will offer the first concrete look at the profitability impact of the new pricing strategy. Analysts at UBS maintain a 'Neutral' rating with a price target of 332 Danish kroner but see room for the company to raise the lower end of its growth forecast—provided margin development is supportive.

Parallel to its commercial maneuvers, the company continues to execute a share buyback program of up to DKK 15 billion. By early April, it had already repurchased nearly 10 million B-shares at an average price of around DKK 259.

On the product pipeline front, developments are mixed. The U.S. FDA approved the higher-dose Wegovy HD (7.2 mg semaglutide) in March, with a planned U.S. launch in April. Data from the STEP UP study showed participants achieved an average weight loss of 20.7%, with about one-third losing more than 25%. Conversely, the company's foray into Alzheimer's disease has ended. The EVOKE and EVOKE+ studies found that oral semaglutid provided no clinical benefit in early Alzheimer's disease, leading to the program's termination in November 2025.

Looking ahead, key milestones in the second half of the year include an EU regulatory decision on the oral Wegovy tablet and data from the Phase III HIBISCUS study for etavopivat in sickle cell disease. Management is also scaling up its own oral Wegovy variant, with early data suggesting stronger weight loss compared to rival compounds like orforglipron. New market data supports the thesis that oral drugs primarily tap new patient populations rather than cannibalizing injectable users.

The first-quarter report will be a critical indicator of whether Novo Nordisk can stabilize its conservative annual forecast and begin to rebuild investor confidence in a rapidly evolving market.